Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)

NCT03089658 | Unknown

• 1 other identifier: MS100070_0308
• Study Type: expanded_access
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Expanded access to Avelumab solution for infusion will be made available for adult patients with mMCC whose disease has progressed after receiving at least one prior chemotherapy.

Conditions

Metastatic Merkel Cell Carcinoma

Keywords

Metastatic Merkel Cell Carcinoma; Expanded Access Program; Temporary Authorisation for Use; Avelumab

Interventions

Avelumab DRUG

Avelumab should be administered intravenously as per the recommended dose. Administration of Avelumab should continue according to the recommended schedule until disease progression or unacceptable toxicity.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Measurable metastatic Merkel cell carcinoma according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1), has failed at least one line of adequately dosed chemotherapy in the metastatic setting and has subsequently progressed (where adequate dosing is defined as a minimum of 2 cycles)
• Not eligible for participation in any ongoing clinical trial for Merkel cell carcinoma including the Javelin Merkel 200 study (NCT02155647)
• Adequate hematological, hepatic and renal function as defined in the protocol

You may not qualify if:

• Brain metastases
• Prior organ transplantation, including allogeneic stem cell transplantation
• History of testing positive for human immunodeficiency virus (HIV) or known AIDS or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
• Concurrent, active, malignant disease (other than Merkel cell carcinoma) with the exception of basal or squamous cell carcinoma of the skin or carcinoma in situ as defined in protocol
• Previous or active autoimmune disease requiring systemic immunosuppressive therapy
• Known severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma
• Clinically significant (that is, active) cardiovascular disease: cerebral vascular accident / stroke (\< 6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment) unstable angina, congestive heart failure (New York Heart Association Classification Class ≥ II), or serious cardiac arrhythmia requiring medication
• Persisting toxicity related to prior therapy of Grade \>1 NCI-CTCAE v 4.03 (alopecia and sensory neuropathy Grade ≤ 2 is acceptable)
• Being treated with chronic systemic corticosteroids or other chronic therapeutic immunosuppression
• Pregnant or lactating (for women of childbearing potential)
• Not using a highly effective contraception if the risk of conception exists

Sponsors & Collaborators

• Merck KGaA, Darmstadt, Germany: lead
• Pfizer: collaborator

Study Sites (1)

Avelumab ATU Unit

Lyon, France

Location

MeSH Terms

Conditions

Carcinoma, Merkel Cell

Interventions

avelumab

Condition Hierarchy (Ancestors)

Polyomavirus Infections; DNA Virus Infections; Virus Diseases; Infections; Tumor Virus Infections; Carcinoma, Neuroendocrine; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 20, 2017
• First Posted: March 24, 2017
• Last Updated: October 9, 2019

Record last verified: 2019-10

Locations

FR (1)